Loading people...
Brad Balter is a Vice President at Bain Capital Life Sciences, a leading global private equity firm. He specializes in identifying and executing investment opportunities within the life sciences sector, including biotechnology, pharmaceuticals, and medical devices.
Brad Balter focuses on investments across the life sciences industry. This includes biotechnology, pharmaceuticals, medical devices, diagnostics, and other healthcare innovations, often targeting areas like oncology, rare diseases, and neuroscience.
Brad Balter works as a Vice President at Bain Capital Life Sciences.
Brad Balter is an investment professional at TCG Crossover based in Wellesley, Massachusetts. He previously served as a Vice President at Bain Capital Life Sciences, where he managed trading execution and capital markets for a portfolio that included a $300 million Series A in BMS Autoimmune and a $120 million round for Merida Biosciences. Before transitioning to life sciences venture capital, he founded and served as Chief Executive Officer of Balter Capital Management in 2006 and Balter Liquid Alternatives in 2013 to oversee hedge fund portfolios. His earlier career includes tenures as a Managing Director at Citigroup and in hedge fund coverage at UBS, following his graduation from Williams College and earning his Chartered Financial Analyst designation. Balter currently focuses on alternative investments and life sciences funding across the biopharmaceutical, medical device, and diagnostics sectors.
Brad Balter is a distinguished Vice President at Bain Capital Life Sciences, a leading global private equity firm dedicated to investing in innovative companies across the life sciences industry. In his pivotal role, Mr. Balter contributes significantly to the firm's strategic investment initiatives, focusing on identifying and nurturing groundbreaking ventures that promise to transform patient care and advance medical science. His work involves rigorous due diligence, financial analysis, and strategic partnership development, all aimed at supporting companies poised for substantial growth and impact.
At Bain Capital Life Sciences, Brad Balter's investment focus encompasses a broad spectrum of healthcare innovation. He is deeply involved in evaluating opportunities within biotechnology, pharmaceuticals, medical devices, diagnostics, and other related sectors. His specific interests often align with areas of high unmet medical need, including oncology, rare diseases, neuroscience, and emerging digital health solutions. Mr. Balter's analytical acumen and deep understanding of market dynamics enable him to pinpoint companies with strong scientific foundations, robust pipelines, and compelling commercial potential. He works closely with portfolio companies, providing strategic guidance to help them navigate complex development pathways and achieve their clinical and commercial milestones.
Prior to his current role as Vice President, Brad Balter honed his expertise as an Associate at Bain Capital Life Sciences, gaining invaluable experience in the intricacies of healthcare investing. His journey with Bain Capital began earlier as an Associate within Bain Capital Private Equity, where he contributed to a diverse range of investment strategies across various industries. This foundational experience provided him with a comprehensive understanding of private equity principles and value creation. Before joining Bain Capital, Mr. Balter commenced his career as an Investment Banking Analyst at Goldman Sachs, a role that equipped him with a strong financial toolkit and a disciplined approach to market analysis.
Academically, Brad Balter holds an MBA from Harvard Business School, a testament to his commitment to leadership and strategic management. He also earned a BS in Economics from the Wharton School at the University of Pennsylvania, where he developed a solid grounding in finance and business analytics. While specific individual investments are often a collaborative effort at a firm of Bain Capital's stature, Mr. Balter's contributions are integral to the firm's overall success in backing transformative life sciences companies. His involvement helps drive the growth of companies developing novel therapies and technologies that address critical health challenges globally.
